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Circulating Endothelial Progenitor Cells in Cardiovascular Outcomes
Werner N, Kosiol S, Schiegle T, et al. N Engl J Med 2005;353:99-1007.
Conclusion: Endothelial progenitor cells positive for CD-34 and
kinase domain receptor (KDR) predict occurrence of death from cardiovas-
cular causes and cardiovascular events.
Summary: Endothelial progenitor cells can differentiate into endothe-
lial cells and proliferate. They may be candidates for mediating vascular
regeneration. These cells, derived from the bone marrow, are thought to
support vascular endothelium integrity. Levels of endothelial progenitor
cells correlate inversely with cardiovascular risk factors. The authors sought
to study the prognostic value associated with circulating endothelial progen-
itor cells.
Endothelial progenitor cells positive for CD-34 and KDR were deter-
mined using flow cytometry. Five hundred and nineteen patients with
coronary artery disease confirmed by angiography were studied. After twelve
months of follow-up, association between death from cardiovascular causes,
the occurrence of a first major cardiovascular event (defined as myocardial
infarction, hospitalization, revascularization, or death from cardiovascular
cause), revascularization, hospitalization, and death from all causes was
correlated with baseline levels of endothelial progenitor cells.
Two hundred and fourteen patients had a first major cardiovascular
event, 43 participants died, with 23 of these deaths from cardiovascular
causes. Adjusting for age, vascular risk factors, sex, and other variables
relevant to cardiovascular disease, increased levels of endothelial progenitor
cells were associated with a reduced risk of a first major cardiovascular event
(Hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.62 to 0.89; P 
.002), death from cardiovascular causes, (HR 0.31; 95% CI 0.16 to 0.63;
P  .001), hospitalization (HR 0.76; 95% CI 0.63 to 0.94; P  .01), and
revascularization (HR 0.77; 95% CI 0.62 to 0.95; P  .02). Myocardial
infarction and death from all causes were not predicted by endothelial
progenitor-cell levels.
Comment: The role of endothelial progenitor cells in rejuvenation of
vascular endothelium is currently an area of intensive investigation. It
appears these immature cells may modify the pathogenesis of atherosclerotic
disease. Measurement of endothelial progenitor cells may improve risk
stratification in patients with cardiovascular disease.
Evaluation of the Safety and Effectiveness of Renal Artery Stenting
After Unsuccessful Balloon Angioplasty: The ASPIRE-2 Study
Rocha-Singh K, Jaff MR, Rosenfield K, and the ASPIRE-2Trial Investigators.
J Am Coll Cardiol 2005;46:776-83.
Conclusion: Balloon-expandable stents in hypertensive patients with
ostial renal artery atherosclerotic stenosis can have a beneficial impact on
hypertension when initial transluminal angioplasty is unsuccessful.
Summary: The authors sought to define safety and durability of renal
artery stents following suboptimal or failed renal artery angioplasty when
renal vascular hypertension was suspected. This was a non randomized study
that enrolled 208 patients with either primary or restenontic (70%) ostial
renal artery stenosis. All patients underwent placement of a balloon-expandable
stent following an unsuccessful transluminal angioplasty. Unsuccessful
transluminal renal artery angioplasty was defined as 50% residual stenosis,
flow limiting dissection, or a persistent trans-lesion pressure gradient. Pri-
mary end point was restenosis at 9 months as determined by angiogram or
duplex scanning. Secondary end points included blood pressure, cumulative
adverse events, renal function, and target lesion revascularization at 24
months.
In 80.2% of cases, placement of the stent was immediately successful
(n  182 of 227). Nine month restensosis rate was 17.4%. Systolic blood
pressure decreased from 168  25 mm/Hg at baseline to 149  24
mm/Hg at 9 months and 149  25 mm/Hg at 24 months (P  .001). At
24 months, the cumulative rate of major adverse events was 19.7%. Serum
creatinine concentrations were unchanged from baseline values at both 9
and 24 months.
Comment: The study is limited by its retrospective nature and lack of
controls in that no patients were treated with medical therapy or simple
balloon angioplasty alone. In addition, primary stenting of renal artery ostial
lesions is currently routine. The study provides reasonable information
regarding recurrent stenosis in a sub group of patients undergoing renal
artery stenting. Overall, however, it is of little relevance to modern practice.
Risk of Major Haemorrhage in Patients After Infra-Inguinal Venous
Bypass Surgery: Therapeutic Consequences. The Dutch BOA (Bypass
Oral Anticoagulants or Aspirin) Study
Ariesen NJ, Tangelder MJD, Lawson JA, and the Dutch Bypass Oral
Anticoagulants or Aspirin (BOA) Study. Eur J Vasc Endo Surg 2005;30:
154-159.
Conclusion: Even considering the risk of hemorrhage, it is recom-
mended patients following peripheral venous bypass surgery be routinely
treated with oral anticoagulants.
Summary: The Dutch Bypass Oral Anticoagulants or Aspirin (BOA)
study indicated oral anticoagulants were more effective than aspirin in
preventing occlusion of lower extremity vein bypass grafts (Hazard Ratio)
0.69, 95% CI 0.54-0.88. Lancet 2000;355:1186-1187). In the BOA study,
however, there was two-fold increase risk of bleeding complications in
patients treated with oral anticoagulants following peripheral bypass surgery
(HR 1.96, 95% CI 1.42-2.71). In this study, the authors developed a model
to identify patients treated with anticoagulation who are at risk of major
hemorrhage. They also included in their model an estimation of whether
hemorrhage could be prevented by the use of aspirin rather than by the use
of oral anticoagulants.
Data of patients in the BOA study was reanalyzed with Cox regression
techniques. In the BOA study, there were 1,326 patients randomized to oral
anticoagulants and 1,324 randomized to aspirin.
There was an increased risk of major hemorrhage in patients on
anticoagulants associated with systolic blood pressure greater than 140
mm/Hg (HR 1.62), diabetes mellitus (HR 1.60), and age 75 years
(HR 2.77). Stratifying patients according to risks quartiles; if patients in
the highest risk quartile had received aspirin rather than anticoagulants,
the number of patients with major hemorrhage would, according to the
model, have been reduced from 46 to 22. This would have been
associated with no major changes in ischemic events or graft occlusions.
In the subgroup of patients with venous bypasses, a similar analysis
indicated major hemorrhages would be reduced from 27 to 13 patients,
but at a cost of 7 more mostly fatal ischemic events and 17 more graft
occlusions.
Comment: The BOA study is widely known and widely quoted but
thus far its findings have had little influence on the treatment of patients
with peripheral vein bypass grafts. Part of the lack of acceptance of the
BOA recommendations undoubtedly has to do with the increased hem-
orrhage rate with the use of anticoagulants. This analysis suggests that
even with the increased hemorrhage rates using oral anticoagulants,
patients with vein bypasses still benefit overall with oral anticoagulants
compared to aspirin. Although the authors’ model is interesting, this type
of retrospective analysis, in itself, is not going to convince many to utilize
oral anticoagulants as routine prophylaxis against vein bypass graft
occlusion.
Is Duplex Surveillance of Value After Leg Vein Bypass Grafting? The
Principle Results of the Vein Graft Surveillance Randomized Trial
(VGST)
Davies AH, Howdon AG, Thompson SG, and the VGST Participants.
Circulation 2005;112:1985-991.
Conclusion: Intensive postoperative graft surveillance with duplex
scanning following lower extremity vein bypass graft operations does not
result in lower amputation rates than a simple program of clinical surveil-
lance.
Summary: This was a multicenter, randomized, prospective, con-
trolled clinical trial. There were 594 patients with a patent vein graft 30 days
following surgery. These patients were randomized to either clinical follow
up alone or a duplex follow up program with studies at 6 weeks and then 3,
6, 9, 12, and 18 months postoperatively. Approximately 2/3 of the grafts
were placed for critical ischemia with 2/3 of the distal anastomoses to the
popliteal artery either above or below the knee. Approximately 1/3 of the
patients in each group had diabetes and the median age was 70 years in each
group. Ipsilateral greater saphenous vein was used in 92% of the clinical
follow up group and 94% of the duplex follow up group.
There are no differences in the clinical and duplex surveillance groups
with respect to amputation rates (7% for each group) or vascular mortality
(3% v 4%) at 18 months. There were more stenoses at 18 months in the
clinical group (19% v 12% P  .04). Primary patency, primary assisted
patency, and secondary patency were similar in the clinical group (69%, 75%,
and 80% and the duplex group 67%, 76%, and 79%). There were no apparent
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